A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumoursEdwina N. Scott, Johann S. de Bono, Anne Thomas et al.|Cancer Chemotherapy and Pharmacology|2009Cited by 34
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationJoaquı́n Mateo, L Rhoda Molife, Anitra Fielding et al.|Unknown|2013Cited by 19
Targeting cell cycle kinases and kinesins in anticancer drug developmentTimothy A. Yap, Johann S. de Bono, Sarah P. Blagden et al.|Expert Opinion on Drug Discovery|2007Cited by 15